Latest Articles
Hugh Taylor, MD, approved therapies for endometriosis pain - Contemporary OB/GYN
Hugh Taylor, MD, approved therapies for endometriosis pain Contemporary OB/GYN
Published: Sept. 24, 2026, 8:53 p.m.
Hugh Taylor, MD, discusses first- and second-line medical therapy for endometriosis - Contemporary OB/GYN
Hugh Taylor, MD, discusses first- and second-line medical therapy for endometriosis Contemporary OB/GYN
Published: Sept. 24, 2026, 8:21 p.m.
Absci Corporation Announces Preliminary Details for Phase 2 Storyline? Trial of Ai-Designed Antibody Abs-201? for Endometriosis - marketscreener.com
Absci Corporation Announces Preliminary Details for Phase 2 Storyline? Trial of Ai-Designed Antibody Abs-201? for Endometriosis marketscreener.com
Published: Sept. 24, 2026, 1:52 p.m.
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027 - Investing.com
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027 Investing.com
Published: Sept. 24, 2026, 12:51 p.m.
UF’s ECE’s Laura Kim Gets NIH Grant For Quantum Endometriosis Study - quantumzeitgeist.com
UF’s ECE’s Laura Kim Gets NIH Grant For Quantum Endometriosis Study quantumzeitgeist.com
Published: Sept. 24, 2026, 12:37 p.m.
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027 - Yahoo Finance
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027 Yahoo Finance
Published: Sept. 24, 2026, 12:18 p.m.
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - The Manila Times
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis The Manila Times
Published: Sept. 24, 2026, 12:10 p.m.
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - manilatimes.net
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis manilatimes.net
Published: Sept. 24, 2026, 12:10 p.m.
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027 - Investing.com UK
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027 Investing.com UK
Published: Sept. 24, 2026, 12:06 p.m.
Endometriosis affects roughly 1 in 10 women of reproductive age. Absci plans a drug trial in about 150 patients. - Stock Titan
Endometriosis affects roughly 1 in 10 women of reproductive age. Absci plans a drug trial in about 150 patients. Stock Titan
Published: Sept. 24, 2026, noon
Link copied to clipboard!